Genmab A/S, one of Europe’s oldest antibody companies, has registered to make a public offering of American Depositary Shares on the US Nasdaq market of up to $500 million. The plans were disclosed on 28 May but as of 6 June the final size of the offering had not been decided. The company is currently listed on Nasdaq Copenhagen and is proposing the US listing to broaden its shareholder base.
